About Sutro Biopharma

At Sutro Biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics.  Our focus is aimed primarily on next generation cancer therapeutics — Antibody Conjugates and Bispecific Antibodies. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.

Learn More

Technology

Our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency.

Learn More

Pipeline

Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies, and antibody-based therapeutics targeting immuno-oncology pathways.

Learn More

Recent News

07Jun

SutroVax Announces $85M Series C Financing led by TPG Growth

SutroVax Announces $85M Series C Financing led by TPG Growth.. Read More →
31May

Sutro CEO, Bill Newell appointed Chair of the California Life Sciences Association.

California Life Sciences Association Elects New Board Chair, Vice Chair and Adds New Board Member    .. Read More →

Careers

At Sutro, collaboration drives how we achieve results. By putting the goals of the Company first, we aim to make a difference both as individuals and as part of a team.

Learn More